Genocea to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Genocea Biosciences, Inc. (NASDAQ: GNCA) announced that CEO Chip Clark will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available as a webcast starting March 9 at 7:00 A.M. ET on the investor section of the Genocea website, where it will remain archived for approximately 90 days. Genocea focuses on developing personalized cancer immunotherapies using its ATLAS™ platform to identify effective antigens for treatment.

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.genocea.com, beginning on Tuesday, March 9, 2021 at 7:00 A.M. ET.

Following the conclusion of the conference, the presentation will remain archived on the Genocea website for approximately 90 days.

About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our proprietary ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy using neoantigen-targeted peripheral cells for which we are commencing a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in identifying meaningful therapies. To learn more, please visit https://www.genocea.com.

Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com 

FAQ

When will Genocea Biosciences be presenting at the H.C. Wainwright Global Life Sciences Conference?

Genocea Biosciences will present on March 9-10, 2021.

Where can I watch the Genocea presentation from the H.C. Wainwright Conference?

The presentation will be available on Genocea's investor website starting March 9, 2021, at 7:00 A.M. ET.

How long will the Genocea presentation remain available online?

The presentation will be archived for approximately 90 days after the conference.

What is the focus of Genocea Biosciences?

Genocea focuses on developing personalized cancer immunotherapies using its proprietary ATLAS™ platform.

What clinical programs is Genocea currently advancing?

Genocea is advancing two programs: GEN-009, a neoantigen vaccine, and GEN-011, an adoptive T cell therapy.